RU2016113713A - Комбинации nsaid и лигандов сигма-рецепторов - Google Patents
Комбинации nsaid и лигандов сигма-рецепторов Download PDFInfo
- Publication number
- RU2016113713A RU2016113713A RU2016113713A RU2016113713A RU2016113713A RU 2016113713 A RU2016113713 A RU 2016113713A RU 2016113713 A RU2016113713 A RU 2016113713A RU 2016113713 A RU2016113713 A RU 2016113713A RU 2016113713 A RU2016113713 A RU 2016113713A
- Authority
- RU
- Russia
- Prior art keywords
- pyrazol
- dichlorophenyl
- yloxy
- methyl
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382353.4 | 2013-09-12 | ||
| EP13382353 | 2013-09-12 | ||
| PCT/EP2014/069370 WO2015036470A1 (en) | 2013-09-12 | 2014-09-11 | Nsaid and sigma receptor ligand combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016113713A true RU2016113713A (ru) | 2017-10-17 |
| RU2016113713A3 RU2016113713A3 (enExample) | 2018-06-29 |
Family
ID=49223707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016113713A RU2016113713A (ru) | 2013-09-12 | 2014-09-11 | Комбинации nsaid и лигандов сигма-рецепторов |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160220574A1 (enExample) |
| EP (1) | EP3043795A1 (enExample) |
| JP (1) | JP2016530322A (enExample) |
| KR (1) | KR20160054547A (enExample) |
| CN (1) | CN105611925A (enExample) |
| AR (1) | AR100021A1 (enExample) |
| AU (1) | AU2014320399A1 (enExample) |
| CA (1) | CA2922330A1 (enExample) |
| IL (1) | IL244200A0 (enExample) |
| MA (1) | MA38957B1 (enExample) |
| MX (1) | MX2016002892A (enExample) |
| PH (1) | PH12016500356A1 (enExample) |
| RU (1) | RU2016113713A (enExample) |
| SG (1) | SG11201601304XA (enExample) |
| TN (1) | TN2016000084A1 (enExample) |
| TW (1) | TW201605433A (enExample) |
| WO (1) | WO2015036470A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| SG11201604480PA (en) | 2013-12-17 | 2016-07-28 | Esteve Labor Dr | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS |
| CN107459510B (zh) * | 2016-06-06 | 2021-06-25 | 华东师范大学 | 异恶唑类化合物及其应用 |
| EP3415143A1 (en) * | 2017-06-16 | 2018-12-19 | Kai-Uwe Kern | Bromhexine for the treatment of pain |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP3993901A1 (en) * | 2019-07-03 | 2022-05-11 | ExxonMobil Research and Engineering Company | Metal-organic framework materials comprising a pyrazolylbenzoate ligand and methods for production thereof |
| EP4233854A3 (en) * | 2019-11-01 | 2024-01-17 | Piedmont Animal Health Inc. | Therapeutic formulations and uses thereof |
| WO2024105225A1 (en) * | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
| CN120860019A (zh) * | 2024-04-30 | 2025-10-31 | 厦门大学 | 氯苯唑酸在激活rxr活性中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068838B1 (en) * | 1981-06-26 | 1986-09-17 | The Upjohn Company | Analgesic process and composition |
| AU2062892A (en) * | 1991-08-16 | 1993-02-18 | Mcneil-Ppc, Inc. | Potentiation of antitussive effect of dextromethorphan |
| AU2005276590B2 (en) * | 2004-08-27 | 2011-05-19 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| EP1634872A1 (en) * | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
| EP2116539A1 (en) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2292236A1 (en) * | 2009-08-14 | 2011-03-09 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| EP2353598A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2460519A1 (en) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
| EP2524694A1 (en) * | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| BR112015010196A2 (pt) * | 2012-11-05 | 2017-07-11 | Zafgen Inc | métodos de tratar doença do fígado |
-
2014
- 2014-09-11 MX MX2016002892A patent/MX2016002892A/es unknown
- 2014-09-11 JP JP2016542304A patent/JP2016530322A/ja active Pending
- 2014-09-11 AR ARP140103392A patent/AR100021A1/es unknown
- 2014-09-11 WO PCT/EP2014/069370 patent/WO2015036470A1/en not_active Ceased
- 2014-09-11 AU AU2014320399A patent/AU2014320399A1/en not_active Abandoned
- 2014-09-11 RU RU2016113713A patent/RU2016113713A/ru not_active Application Discontinuation
- 2014-09-11 TN TN2016000084A patent/TN2016000084A1/en unknown
- 2014-09-11 SG SG11201601304XA patent/SG11201601304XA/en unknown
- 2014-09-11 EP EP14762005.8A patent/EP3043795A1/en not_active Withdrawn
- 2014-09-11 US US15/021,050 patent/US20160220574A1/en not_active Abandoned
- 2014-09-11 TW TW103131340A patent/TW201605433A/zh unknown
- 2014-09-11 CA CA2922330A patent/CA2922330A1/en not_active Abandoned
- 2014-09-11 KR KR1020167009124A patent/KR20160054547A/ko not_active Withdrawn
- 2014-09-11 CN CN201480050356.4A patent/CN105611925A/zh active Pending
-
2016
- 2016-02-21 IL IL244200A patent/IL244200A0/en unknown
- 2016-02-23 PH PH12016500356A patent/PH12016500356A1/en unknown
- 2016-04-07 MA MA38957A patent/MA38957B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016530322A (ja) | 2016-09-29 |
| MA38957A1 (fr) | 2016-04-29 |
| US20160220574A1 (en) | 2016-08-04 |
| PH12016500356A1 (en) | 2016-05-16 |
| MA38957B1 (fr) | 2016-11-30 |
| AR100021A1 (es) | 2016-09-07 |
| CN105611925A (zh) | 2016-05-25 |
| MX2016002892A (es) | 2016-06-10 |
| TN2016000084A1 (en) | 2017-07-05 |
| TW201605433A (zh) | 2016-02-16 |
| IL244200A0 (en) | 2016-04-21 |
| EP3043795A1 (en) | 2016-07-20 |
| CA2922330A1 (en) | 2015-03-19 |
| SG11201601304XA (en) | 2016-03-30 |
| WO2015036470A1 (en) | 2015-03-19 |
| AU2014320399A1 (en) | 2016-03-10 |
| KR20160054547A (ko) | 2016-05-16 |
| RU2016113713A3 (enExample) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016113713A (ru) | Комбинации nsaid и лигандов сигма-рецепторов | |
| JP2016530322A5 (enExample) | ||
| JP2014501732A5 (enExample) | ||
| JP2011518807A5 (enExample) | ||
| RU2010147925A (ru) | 1-арил-3-аминоалкоксипиразолы как сигма-лиганды, усиливающие обезболивающее действие опиоидов и ослабляющие зависимость от них | |
| RU2013130222A (ru) | Применение сигма-лигандов от боли при раке костей | |
| JP2013532709A5 (enExample) | ||
| JP2017503765A5 (enExample) | ||
| RU2016102149A (ru) | Применение сигма-лигандов для предотвращения и лечения боли, связанной с интерстициальным циститом/синдромом раздраженного мочевого пузыря (иц/срмп) | |
| JP2016540771A5 (enExample) | ||
| RU2012137506A (ru) | Сигма-лиганды для потенцирования анальгетического эффекта опиоидов и опиатов при послеоперационной боли и для ослабления зависимости от них | |
| RU2015148766A (ru) | Комбинации лигандов альфа-2 адренорецептора и сигма рецептора | |
| RU2013156367A (ru) | Применение сигма-лигандов при боли, связанной с диабетом 2 типа | |
| JP2016523276A5 (enExample) | ||
| JP2013529206A5 (enExample) | ||
| JP2014518869A5 (enExample) | ||
| CA2576144A1 (en) | Sigma receptor inhibitors | |
| JP2016516792A5 (enExample) | ||
| RU2009131454A (ru) | Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств | |
| DK2576543T3 (en) | Pyrazole compounds as sigma receptor inhibitors | |
| IL284073B2 (en) | Heterocyclic compound and salt thereof, medicament, and the compound or salt for use in preventing or treating narcolepsy | |
| JP2016535772A5 (enExample) | ||
| PE20080895A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| JP2014511869A5 (enExample) | ||
| PE20190345A1 (es) | Combinaciones de compuestos activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181015 |